查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
2128085

2026年至2034年醫藥研發受託製造廠商（CDMO）外包市場規模、佔有率、成長、全球產業分析、區域趨勢及預測

Contract Development and Manufacturing Organization Outsourcing Market Size, Share, Growth and Global Industry Analysis, Regional Insights and Forecast to 2026-2034
出版日期: | 出版商: Fortune Business Insights Pvt. Ltd. | 英文 150 Pages | 商品交期: 2-3個工作天內

價格

推動醫藥研發和受託製造廠商（CDMO）外包市場成長要素

全球合約研發受託製造廠商（CDMO）外包市場預計將在2025年達到1,992.7億美元，2026年成長至2,149.5億美元，並在2034年達到4,199.3億美元，預測期內複合年成長率（CAGR）為8.7%。隨著製藥和生技公司擴大將藥物研發、生產、分析測試、包裝和法規事務等服務外包給專業的CDMO，該市場正在快速擴張。外包使製藥研發公司能夠降低資本支出、縮短產品上市時間、提高營運效率並利用更先進的生產技術。

生物製藥、細胞和基因療法、高活性原料藥、無菌注射劑以及mRNA產品的需求不斷成長，進一步凸顯了對擁有專業設施和法規專業知識的經驗豐富的CDMO合作夥伴的需求。研發投入的增加、藥物研發管線的擴展以及全球臨床試驗數量的上升也是推動市場發展的重要因素。

龍沙、賽默飛世爾科技、Catalent、三星生物製劑和藥明生物等領先企業不斷擴大其生產能力，收購專業設施，並推出綜合開發平台，以加強其全球影響力。

市場趨勢

影響CDMO外包市場的關鍵趨勢之一是對整合式端到端外包平台的需求日益成長。製藥公司越來越傾向於選擇能夠處理製劑開發、分析測試、臨床生產、商業化生產、包裝和法規遵循等所有環節的單一合作夥伴。這種整合式方法可以降低專案複雜性，縮短開發週期，並提高供應鏈效率。

此外，生物製藥生產、連續生產技術、數位化品管系統以及人工智慧驅動的製程最佳化等技術的日益普及也在改變著整個產業。各公司正大力投資先進製造技術，以提高生產效率並確保嚴格遵守監管規定。

市場促進因素

市場成長的主要驅動力是生物技術和製藥公司擴大將藥品生產外包。建造先進的生產設施需要巨額投資、高技能人才和嚴格的監管合規要求。外包使公司能夠降低營運風險，從而專注於藥物研發和商業化。

生物製藥、生物相似藥、癌症治療藥物、疫苗、抗體藥物複合體（ADC）和個人化醫療的快速發展顯著提升了對專業CDMO服務的需求。臨床試驗活動的活性化和對靈活生產能力日益成長的需求也持續推動市場擴張。

市場限制因素

儘管預計市場將保持強勁成長，但由於建造最先進的製藥生產設施需要極高的資本投入，該市場仍面臨挑戰。建造符合監管規定的生產工廠、驗證生產流程以及獲得監管部門的批准，都需要大量的資金和漫長的開發週期。

此外，維持良好生產規範 (GMP) 標準並遵守全球監管要求可能會導致營運成本增加，尤其是對於小規模的服務供應商。

市場機遇

先進生物製藥、細胞和基因療法、病毒載體、mRNA產品、胜肽療法以及高活性原料藥的出現，為合約研發生產機構（CDMO）帶來了巨大的機會。這些複雜的療法需要高度專業的研發和生產能力，因此許多製藥公司傾向於將這些流程外包。

隨著亞太地區、北美和歐洲的戰略聯盟、合併、收購和設施擴張不斷增加，我們預計在預測期內將出現新的商機。

市場挑戰

CDMO面臨的最大挑戰之一是如何在多個國際市場中保持嚴格的監管合規性。生產缺陷、污染風險、技術轉移延誤、文件錯誤以及監管檢查都可能對生產計劃和公司聲譽產生重大影響。

此外，營運成本上升、供應鏈中斷以及全球CDMO供應商之間日益激烈的競爭，都持續對利潤率造成越來越大的壓力。

細分分析

從所提供的服務來看，預計到2025年，契約製造領域將佔據市場主導地位，這主要得益於製藥公司對商業規模生產、原料藥生產、生物製藥生產、無菌灌裝和包裝等環節外包需求的增加。而合約研發領域預計將成長更為迅猛，這主要受製劑研發、分析測試、製程最佳化和法規遵從支援等需求不斷成長的推動。

按分子類型分類，小分子藥物佔據最大的市場佔有率，這得益於對學名藥、專科藥物和抗癌藥物的強勁需求，預計到2026年將佔市場佔有率的52.5%。同時，隨著生技藥品生技藥品預計將實現強勁成長。

按治療領域分類，腫瘤領域是市場成長的主要驅動力，這主要歸功於大量抗癌候選藥物需要複雜的生產過程和專業的生產能力。預計到2026年，腫瘤領域將佔全球市場的25.5%。

區域展望

由於全球製藥公司的強大實力、先進的製造基礎設施以及對生物製藥生產的持續投資，北美預計將引領全球CDMO外包市場，到2025年市場規模將達到690.6億美元。預計到2026年，美國市場規模將達到667.8億美元，仍將是最大的國內市場。

在嚴格的GMP標準、先進的生物製藥生產能力以及眾多專業CDMO的推動下，預計到2026年，歐洲生物製藥市場規模將達到564.7億美元。德國和英國將繼續成為該地區成長的主要驅動力。

預計到2026年，亞太地區市場規模將達到563億美元，這主要得益於藥品製造業的擴張、成本效益高的生產能力、國內藥品需求的成長以及中國、印度、日本、韓國和新加坡等國投資的增加。中國和印度作為首選外包目的地，其全球地位正不斷鞏固。

世界其他地區預計將實現溫和成長，這得益於南美洲、中東和非洲地區對製藥業投資的增加。

目錄

第1章：引言

第2章執行摘要

第3章 市場動態

  • 市場促進因素
  • 市場限制因素
  • 市場機遇
  • 市場挑戰
  • 市場趨勢

第4章：主要考慮因素

  • 合約研發生產組織（CDMO）的發展
  • 主要國家和地區監管狀況概述
  • 產業重大發展動態－（合併、收購、合作等）

第5章：全球藥品研發受託製造廠商（CDMO）外包市場分析、洞察與預測（2021-2034年）

  • 市場分析、洞察與預測：按服務分類
    • 契約製造
      • API生產
      • 成品
      • 包裝
    • 合約開發
      • 配方開發
      • 製程開發和規模化
      • 分析方法的開發與驗證
      • 穩定性測試
      • CMC和法規遵從性開發支持
      • 其他
  • 市場分析、洞察與預測：按分子類型
    • 小分子藥物
    • 生技藥品
    • 細胞和基因治療
    • 其他
  • 市場分析、洞察與預測：按治療領域分類
    • 腫瘤學
    • 感染疾病
    • 神經病學
    • 循環系統
    • 免疫學和炎症
    • 代謝性疾病
    • 其他
  • 市場分析、洞察與預測：按地區分類
    • 北美洲
    • 歐洲
    • 亞太地區
    • 世界其他地區

第6章：北美藥品研發受託製造廠商（CDMO）外包市場分析、洞察與預測（2021-2034年）

  • 國家
    • 美國
    • 加拿大

第7章：歐洲合約開發與受託製造廠商（CDMO）外包市場分析、洞察與預測（2021-2034年）

第8章：亞太地區合約開發與受託製造廠商（CDMO）外包市場分析、洞察與預測（2021-2034年）

第9章：全球合約開發與受託製造廠商（CDMO）外包市場分析、洞察與預測（2021-2034年）

第10章 競爭分析

  • 全球市佔率分析（2024 年）
  • 公司簡介
    • Lonza
    • Thermo Fisher Scientific Inc.
    • Catalent, Inc
    • Samsung Biologics
    • WuXi Biologics
    • Siegfried Holding AG
    • FUJIFILM Holdings Corporation
    • Boehringer Ingelheim International GmbH
    • Recipharm AB
    • Cambrex Corporation
Product Code: FBI102502

Growth Factors of Contract Development & Manufacturing Organization (CDMO) Market

The global Contract Development & Manufacturing Organization (CDMO) market was valued at USD 199.27 billion in 2025 and is expected to grow from USD 214.95 billion in 2026 to USD 419.93 billion by 2034, registering a CAGR of 8.7% during the forecast period. The market is expanding rapidly as pharmaceutical and biotechnology companies increasingly outsource drug development, manufacturing, analytical testing, packaging, and regulatory services to specialized CDMOs. Outsourcing enables drug developers to reduce capital investment, accelerate commercialization timelines, improve operational efficiency, and gain access to advanced manufacturing technologies.

Growing demand for biologics, cell and gene therapies, high-potency APIs, sterile injectables, and mRNA-based products is further strengthening the need for experienced CDMO partners with specialized facilities and regulatory expertise. The market is also benefiting from increasing investments in research and development, rising pharmaceutical pipelines, and the growing number of clinical trials worldwide.

Leading companies such as Lonza, Thermo Fisher Scientific Inc., Catalent, Samsung Biologics, and WuXi Biologics continue expanding their manufacturing capacities, acquiring specialized facilities, and launching integrated development platforms to strengthen their global presence.

Market Trends

A major trend shaping the CDMO market is the growing preference for integrated end-to-end outsourcing platforms. Pharmaceutical companies increasingly prefer a single partner capable of handling formulation development, analytical testing, clinical manufacturing, commercial production, packaging, and regulatory support. This integrated approach reduces project complexity, shortens development timelines, and improves supply chain efficiency.

The growing adoption of biologics manufacturing, continuous manufacturing technologies, digital quality management systems, and AI-driven process optimization is also transforming the industry. Companies are investing heavily in advanced manufacturing technologies to improve production efficiency and regulatory compliance.

Market Drivers

The primary driver of market growth is the increasing outsourcing of pharmaceutical manufacturing by biotech and pharmaceutical companies. Developing modern manufacturing facilities requires enormous investments, highly skilled personnel, and strict regulatory compliance. Outsourcing allows companies to focus on drug discovery and commercialization while reducing operational risks.

The rapid expansion of biologics, biosimilars, oncology therapies, vaccines, antibody-drug conjugates (ADCs), and personalized medicines has significantly increased demand for specialized CDMO services. Growing clinical trial activities and rising demand for flexible manufacturing capacity continue supporting market expansion.

Market Restraints

Despite strong growth prospects, the market faces challenges due to the extremely high capital investment required to establish advanced pharmaceutical manufacturing facilities. Building compliant production plants, validating manufacturing processes, and obtaining regulatory approvals require substantial financial resources and long development timelines.

In addition, maintaining Good Manufacturing Practice (GMP) standards and meeting global regulatory requirements increases operational costs, particularly for smaller service providers.

Market Opportunities

The emergence of advanced biologics, cell and gene therapies, viral vectors, mRNA products, peptide therapeutics, and high-potency APIs presents significant opportunities for CDMOs. These complex therapies require highly specialized development and manufacturing capabilities that many pharmaceutical companies prefer to outsource.

Increasing strategic partnerships, mergers, acquisitions, and facility expansions across Asia Pacific, North America, and Europe are expected to create new revenue opportunities throughout the forecast period.

Market Challenges

One of the biggest challenges for CDMOs is maintaining strict regulatory compliance across multiple international markets. Manufacturing failures, contamination risks, technology transfer delays, documentation errors, and regulatory inspections can significantly impact production schedules and company reputation.

Additionally, rising operational costs, supply chain disruptions, and increasing competition among global CDMO providers continue creating pressure on profit margins.

Segmentation Analysis

Based on service, the contract manufacturing segment dominated the market in 2025 as pharmaceutical companies increasingly outsourced commercial-scale manufacturing, API production, biologics manufacturing, sterile fill-finish, and packaging operations. The contract development segment is expected to witness faster growth due to increasing demand for formulation development, analytical testing, process optimization, and regulatory support.

By molecule type, small molecules accounted for the largest market share and are projected to represent 52.5% of the market in 2026, supported by strong demand for generic drugs, specialty medicines, and oncology products. Meanwhile, the biologics segment is expected to record strong growth as biologic therapies continue expanding worldwide.

Based on therapeutic area, the oncology segment dominated the market due to the large number of cancer drug candidates requiring complex manufacturing and specialized production capabilities. Oncology is projected to account for 25.5% of the global market in 2026.

Regional Outlook

North America dominated the global CDMO market with a value of USD 69.06 billion in 2025, supported by the strong presence of global pharmaceutical companies, advanced manufacturing infrastructure, and continuous investments in biologics production. The U.S. market is projected to reach USD 66.78 billion by 2026, remaining the largest national market.

Europe is projected to reach USD 56.47 billion in 2026, driven by stringent GMP standards, advanced biologics manufacturing capabilities, and the presence of numerous specialized CDMOs. Germany and the U.K. remain key contributors to regional growth.

Asia Pacific is expected to reach USD 56.30 billion in 2026, supported by expanding pharmaceutical manufacturing, cost-efficient production capabilities, growing domestic drug demand, and increasing investments across China, India, Japan, South Korea, and Singapore. China and India continue strengthening their global positions as preferred outsourcing destinations.

The Rest of the World is projected to experience moderate growth, supported by increasing investments in pharmaceutical manufacturing across Latin America, the Middle East, and Africa.

Competitive Landscape

The global CDMO market remains highly competitive, with major companies continuously investing in manufacturing expansion, advanced biologics capabilities, and integrated service platforms. Industry leaders are strengthening their competitive positions through acquisitions, strategic collaborations, digital manufacturing technologies, and expansion into emerging pharmaceutical markets.

Companies are increasingly focusing on biologics manufacturing, sterile injectable production, viral vectors, mRNA technologies, high-potency APIs, and integrated development services to meet the growing outsourcing requirements of global pharmaceutical and biotechnology companies.

Conclusion

The global Contract Development & Manufacturing Organization (CDMO) market is positioned for sustained long-term growth, increasing from USD 199.27 billion in 2025 to USD 214.95 billion in 2026, and projected to reach USD 419.93 billion by 2034. Rising pharmaceutical outsourcing, expanding biologics pipelines, growing demand for advanced therapies, and continuous technological innovation will remain the primary drivers of market expansion. As pharmaceutical companies increasingly rely on specialized manufacturing partners to improve efficiency and reduce development costs, CDMOs with integrated capabilities, regulatory expertise, and advanced manufacturing infrastructure will continue strengthening their global market leadership.

Segmentation By Service, Molecule Type, Therapeutic Area, and Region

By Service * Contract Manufacturing

    • API Manufacturing
    • Finished Product
  • Solid Dosage Forms
  • Injectables
  • Others
    • Packaging
  • Contract Development
    • Formulation Development
    • Process Development & Scale-up
    • Analytical Method Development & Validation
    • Stability Testing
    • CMC & Regulatory Development Support
    • Others

By Molecule Type * Small Molecules

  • Biologics
  • Cell & Gene Therapies
  • Others

By Therapeutic Area * Oncology

  • Infectious Diseases
  • Neurology
  • Cardiology
  • Immunology & Inflammation
  • Metabolic Disorders
  • Others

By Region * North America (By Service, Molecule Type, Therapeutic Area, and Country)

    • U.S.
    • Canada
  • Europe (By Service, Molecule Type, Therapeutic Area, and Country/Sub-region)
    • Germany
    • U.K.
    • France
    • Italy
    • Spain
    • Scandinavia
    • Rest of Europe
  • Asia Pacific (By Service, Molecule Type, Therapeutic Area, and Country/Sub-region)
    • China
    • Japan
    • India
    • Australia & New Zealand
    • Rest of Asia Pacific
  • Rest of the World ( By Service, Molecule Type, Therapeutic Area, and Country/Sub-region)

Table of Content

1. Introduction

  • 1.1. Research Scope
  • 1.2. Market Segmentation
  • 1.3. Research Methodology
  • 1.4. Definitions and Assumptions

2. Executive Summary

3. Market Dynamics

  • 3.1. Market Drivers
  • 3.2. Market Restraints
  • 3.3. Market Opportunities
  • 3.4. Market Challenges
  • 3.5. Market Trends

4. Key Insights

  • 4.1. Advancements in Contract Development & Manufacturing Organization (CDMO)
  • 4.2. Overview of Regulatory Scenario, By Key Countries/Regions
  • 4.3. Key Industry Developments - (Mergers, Acquisitions, & Partnerships, etc.)

5. Global Contract Development & Manufacturing Organization (CDMO) Market Analysis, Insights and Forecast, 2021-2034

  • 5.1. Market Analysis, Insights and Forecast - By Service
    • 5.1.1. Contract Manufacturing
      • 5.1.1.1. API Manufacturing
      • 5.1.1.2. Finished Product
        • 5.1.1.2.1. Solid Dosage Forms
        • 5.1.1.2.2. Injectables
        • 5.1.1.2.3. Others
      • 5.1.1.3. Packaging
    • 5.1.2. Contract Development
      • 5.1.2.1. Formulation Development
      • 5.1.2.2. Process Development & Scale-up
      • 5.1.2.3. Analytical Method Development & Validation
      • 5.1.2.4. Stability Testing
      • 5.1.2.5. CMC & Regulatory Development Support
      • 5.1.2.6. Others
  • 5.2. Market Analysis, Insights and Forecast - By Molecule Type
    • 5.2.1. Small Molecules
    • 5.2.2. Biologics
    • 5.2.3. Cell & Gene Therapies
    • 5.2.4. Others
  • 5.3. Market Analysis, Insights and Forecast - By Therapeutic Area
    • 5.3.1. Oncology
    • 5.3.2. Infectious Diseases
    • 5.3.3. Neurology
    • 5.3.4. Cardiology
    • 5.3.5. Immunology & Inflammation
    • 5.3.6. Metabolic Disorders
    • 5.3.7. Others
  • 5.4. Market Analysis, Insights and Forecast - By Region
    • 5.4.1. North America
    • 5.4.2. Europe
    • 5.4.3. Asia Pacific
    • 5.4.4. Rest of the World

6. North America Contract Development & Manufacturing Organization (CDMO) Market Analysis, Insights and Forecast, 2021-2034

  • 6.1. Market Analysis, Insights and Forecast - By Service
    • 6.1.1. Contract Manufacturing
      • 6.1.1.1. API Manufacturing
      • 6.1.1.2. Finished Product
        • 6.1.1.2.1. Solid Dosage Forms
        • 6.1.1.2.2. Injectables
        • 6.1.1.2.3. Others
      • 6.1.1.3. Packaging
    • 6.1.2. Contract Development
      • 6.1.2.1. Formulation Development
      • 6.1.2.2. Process Development & Scale-up
      • 6.1.2.3. Analytical Method Development & Validation
      • 6.1.2.4. Stability Testing
      • 6.1.2.5. CMC & Regulatory Development Support
      • 6.1.2.6. Others
  • 6.2. Market Analysis, Insights and Forecast - By Molecule Type
    • 6.2.1. Small Molecules
    • 6.2.2. Biologics
    • 6.2.3. Cell & Gene Therapies
    • 6.2.4. Others
  • 6.3. Market Analysis, Insights and Forecast - By Therapeutic Area
    • 6.3.1. Oncology
    • 6.3.2. Infectious Diseases
    • 6.3.3. Neurology
    • 6.3.4. Cardiology
    • 6.3.5. Immunology & Inflammation
    • 6.3.6. Metabolic Disorders
    • 6.3.7. Others
  • 6.4. Market Analysis, Insights and Forecast - By Country
    • 6.4.1. U.S.
    • 6.4.2. Canada

7. Europe Contract Development & Manufacturing Organization (CDMO) Market Analysis, Insights and Forecast, 2021-2034

  • 7.1. Market Analysis, Insights and Forecast - By Service
    • 7.1.1. Contract Manufacturing
      • 7.1.1.1. API Manufacturing
      • 7.1.1.2. Finished Product
        • 7.1.1.2.1. Solid Dosage Forms
        • 7.1.1.2.2. Injectables
        • 7.1.1.2.3. Others
      • 7.1.1.3. Packaging
    • 7.1.2. Contract Development
      • 7.1.2.1. Formulation Development
      • 7.1.2.2. Process Development & Scale-up
      • 7.1.2.3. Analytical Method Development & Validation
      • 7.1.2.4. Stability Testing
      • 7.1.2.5. CMC & Regulatory Development Support
      • 7.1.2.6. Others
  • 7.2. Market Analysis, Insights and Forecast - By Molecule Type
    • 7.2.1. Small Molecules
    • 7.2.2. Biologics
    • 7.2.3. Cell & Gene Therapies
    • 7.2.4. Others
  • 7.3. Market Analysis, Insights and Forecast - By Therapeutic Area
    • 7.3.1. Oncology
    • 7.3.2. Infectious Diseases
    • 7.3.3. Neurology
    • 7.3.4. Cardiology
    • 7.3.5. Immunology & Inflammation
    • 7.3.6. Metabolic Disorders
    • 7.3.7. Others
  • 7.4. Market Analysis, Insights and Forecast - By Countries/Sub-region
    • 7.4.1. Germany
    • 7.4.2. France
    • 7.4.3. U.K.
    • 7.4.4. Italy
    • 7.4.5. Spain
    • 7.4.6. Scandinavia
    • 7.4.7. Rest of the Europe

8. Asia Pacific Contract Development & Manufacturing Organization (CDMO) Market Analysis, Insights and Forecast, 2021-2034

  • 8.1. Market Analysis, Insights and Forecast - By Service
    • 8.1.1. Contract Manufacturing
      • 8.1.1.1. API Manufacturing
      • 8.1.1.2. Finished Product
        • 8.1.1.2.1. Solid Dosage Forms
        • 8.1.1.2.2. Injectables
        • 8.1.1.2.3. Others
      • 8.1.1.3. Packaging
    • 8.1.2. Contract Development
      • 8.1.2.1. Formulation Development
      • 8.1.2.2. Process Development & Scale-up
      • 8.1.2.3. Analytical Method Development & Validation
      • 8.1.2.4. Stability Testing
      • 8.1.2.5. CMC & Regulatory Development Support
      • 8.1.2.6. Others
  • 8.2. Market Analysis, Insights and Forecast - By Molecule Type
    • 8.2.1. Small Molecules
    • 8.2.2. Biologics
    • 8.2.3. Cell & Gene Therapies
    • 8.2.4. Others
  • 8.3. Market Analysis, Insights and Forecast - By Therapeutic Area
    • 8.3.1. Oncology
    • 8.3.2. Infectious Diseases
    • 8.3.3. Neurology
    • 8.3.4. Cardiology
    • 8.3.5. Immunology & Inflammation
    • 8.3.6. Metabolic Disorders
    • 8.3.7. Others
  • 8.4. Market Analysis, Insights and Forecast - By Countries/Sub-region
    • 8.4.1. China
    • 8.4.2. Japan
    • 8.4.3. India
    • 8.4.4. Australia & New Zealand
    • 8.4.5. Rest of Asia Pacific

9. Rest of the World Contract Development & Manufacturing Organization (CDMO) Market Analysis, Insights and Forecast, 2021-2034

  • 9.1. Market Analysis, Insights and Forecast - By Service
    • 9.1.1. Contract Manufacturing
      • 9.1.1.1. API Manufacturing
      • 9.1.1.2. Finished Product
        • 9.1.1.2.1. Solid Dosage Forms
        • 9.1.1.2.2. Injectables
        • 9.1.1.2.3. Others
      • 9.1.1.3. Packaging
    • 9.1.2. Contract Development
      • 9.1.2.1. Formulation Development
      • 9.1.2.2. Process Development & Scale-up
      • 9.1.2.3. Analytical Method Development & Validation
      • 9.1.2.4. Stability Testing
      • 9.1.2.5. CMC & Regulatory Development Support
      • 9.1.2.6. Others
  • 9.2. Market Analysis, Insights and Forecast - By Molecule Type
    • 9.2.1. Small Molecules
    • 9.2.2. Biologics
    • 9.2.3. Cell & Gene Therapies
    • 9.2.4. Others
  • 9.3. Market Analysis, Insights and Forecast - By Therapeutic Area
    • 9.3.1. Oncology
    • 9.3.2. Infectious Diseases
    • 9.3.3. Neurology
    • 9.3.4. Cardiology
    • 9.3.5. Immunology & Inflammation
    • 9.3.6. Metabolic Disorders
    • 9.3.7. Others

10. Competitive Analysis

  • 10.1. Global Market Share Analysis (2024)
  • 10.2. Company Profiles
    • 10.2.1. Lonza
    • 10.2.2. Thermo Fisher Scientific Inc.
    • 10.2.3. Catalent, Inc
    • 10.2.4. Samsung Biologics
    • 10.2.5. WuXi Biologics
    • 10.2.6. Siegfried Holding AG
    • 10.2.7. FUJIFILM Holdings Corporation
    • 10.2.8. Boehringer Ingelheim International GmbH
    • 10.2.9. Recipharm AB
    • 10.2.10. Cambrex Corporation

List of Tables

  • Table 1: Global Contract Development & Manufacturing Organization (CDMO) Market Revenue (USD billion) Forecast, by Service, 2021-2034
  • Table 2: Global Contract Development & Manufacturing Organization (CDMO) Market Revenue (USD billion) Forecast, by Contract Manufacturing, 2021-2034
  • Table 3: Global Contract Development & Manufacturing Organization (CDMO) Market Revenue (USD billion) Forecast, by Finished Product, 2021-2034
  • Table 4: Global Contract Development & Manufacturing Organization (CDMO) Market Revenue (USD billion) Forecast, by Contract Development, 2021-2034
  • Table 5: Global Contract Development & Manufacturing Organization (CDMO) Market Revenue (USD billion) Forecast, by Molecule Type, 2021-2034
  • Table 6: Global Contract Development & Manufacturing Organization (CDMO) Market Revenue (USD billion) Forecast, by Therapeutic Area, 2021-2034
  • Table 7: Global Contract Development & Manufacturing Organization (CDMO) Market Revenue (USD billion) Forecast, by Region, 2021-2034
  • Table 8: North America Contract Development & Manufacturing Organization (CDMO) Market Revenue (USD billion) Forecast, by Service, 2021-2034
  • Table 9: North America Contract Development & Manufacturing Organization (CDMO) Market Revenue (USD billion) Forecast, by Contract Manufacturing, 2021-2034
  • Table 10: North America Contract Development & Manufacturing Organization (CDMO) Market Revenue (USD billion) Forecast, by Finished Product, 2021-2034
  • Table 11: North America Contract Development & Manufacturing Organization (CDMO) Market Revenue (USD billion) Forecast, by Contract Development, 2021-2034
  • Table 12: North America Contract Development & Manufacturing Organization (CDMO) Market Revenue (USD billion) Forecast, by Molecule Type, 2021-2034
  • Table 13: North America Contract Development & Manufacturing Organization (CDMO) Market Revenue (USD billion) Forecast, by Therapeutic Area, 2021-2034
  • Table 14: North America Contract Development & Manufacturing Organization (CDMO) Market Revenue (USD billion) Forecast, by Country, 2021-2034
  • Table 15: Europe Contract Development & Manufacturing Organization (CDMO) Market Revenue (USD billion) Forecast, by Service, 2021-2034
  • Table 16: Europe Contract Development & Manufacturing Organization (CDMO) Market Revenue (USD billion) Forecast, by Contract Manufacturing, 2021-2034
  • Table 17: Europe Contract Development & Manufacturing Organization (CDMO) Market Revenue (USD billion) Forecast, by Finished Product, 2021-2034
  • Table 18: Europe Contract Development & Manufacturing Organization (CDMO) Market Revenue (USD billion) Forecast, by Contract Development, 2021-2034
  • Table 19: Europe Contract Development & Manufacturing Organization (CDMO) Market Revenue (USD billion) Forecast, by Molecule Type, 2021-2034
  • Table 20: Europe Contract Development & Manufacturing Organization (CDMO) Market Revenue (USD billion) Forecast, by Therapeutic Area, 2021-2034
  • Table 21: Europe Contract Development & Manufacturing Organization (CDMO) Market Revenue (USD billion) Forecast, by Country/Sub-region, 2021-2034
  • Table 22: Asia Pacific Contract Development & Manufacturing Organization (CDMO) Market Revenue (USD billion) Forecast, by Service, 2021-2034
  • Table 23: Asia Pacific Contract Development & Manufacturing Organization (CDMO) Market Revenue (USD billion) Forecast, by Contract Manufacturing, 2021-2034
  • Table 24: Asia Pacific Contract Development & Manufacturing Organization (CDMO) Market Revenue (USD billion) Forecast, by Finished Product, 2021-2034
  • Table 25: Asia Pacific Contract Development & Manufacturing Organization (CDMO) Market Revenue (USD billion) Forecast, by Contract Development, 2021-2034
  • Table 26: Asia Pacific Contract Development & Manufacturing Organization (CDMO) Market Revenue (USD billion) Forecast, by Molecule Type, 2021-2034
  • Table 27: Asia Pacific Contract Development & Manufacturing Organization (CDMO) Market Revenue (USD billion) Forecast, by Therapeutic Area, 2021-2034
  • Table 28: Asia Pacific Contract Development & Manufacturing Organization (CDMO) Market Revenue (USD billion) Forecast, by Country/Sub-region, 2021-2034
  • Table 29: Rest of the World Contract Development & Manufacturing Organization (CDMO) Market Revenue (USD billion) Forecast, by Service, 2021-2034
  • Table 30: Rest of the World Contract Development & Manufacturing Organization (CDMO) Market Revenue (USD billion) Forecast, by Contract Manufacturing, 2021-2034
  • Table 31: Rest of the World Contract Development & Manufacturing Organization (CDMO) Market Revenue (USD billion) Forecast, by Finished Product, 2021-2034
  • Table 32: Rest of the World Contract Development & Manufacturing Organization (CDMO) Market Revenue (USD billion) Forecast, by Contract Development, 2021-2034
  • Table 33: Rest of the World Contract Development & Manufacturing Organization (CDMO) Market Revenue (USD billion) Forecast, by Molecule Type, 2021-2034
  • Table 34: Rest of the World Contract Development & Manufacturing Organization (CDMO) Market Revenue (USD billion) Forecast, by Therapeutic Area, 2021-2034

List of Figures

  • Figure 1: Global Contract Development & Manufacturing Organization (CDMO) Market Revenue Breakdown (USD billion, %) by Region, 2025 & 2034
  • Figure 2: Global Contract Development & Manufacturing Organization (CDMO) Market Value Share (%), by Service, 2025 & 2034
  • Figure 3: Global Contract Development & Manufacturing Organization (CDMO) Market Value Share (%), by Molecule Type, 2025 & 2034
  • Figure 4: Global Contract Development & Manufacturing Organization (CDMO) Market Value Share (%), by Therapeutic Area, 2025 & 2034
  • Figure 5: Global Contract Development & Manufacturing Organization (CDMO) Market Value (USD billion), by Region, 2025 & 2034
  • Figure 6: North America Contract Development & Manufacturing Organization (CDMO) Market Value (USD billion), by Service, 2025 & 2034
  • Figure 7: North America Contract Development & Manufacturing Organization (CDMO) Market Value Share (%), by Service, 2025
  • Figure 8: North America Contract Development & Manufacturing Organization (CDMO) Market Value (USD billion), by Molecule Type, 2025 & 2034
  • Figure 9: North America Contract Development & Manufacturing Organization (CDMO) Market Value Share (%), by Molecule Type, 2025
  • Figure 10: North America Contract Development & Manufacturing Organization (CDMO) Market Value (USD billion), by Therapeutic Area, 2025 & 2034
  • Figure 11: North America Contract Development & Manufacturing Organization (CDMO) Market Value Share (%), by Therapeutic Area, 2026
  • Figure 12: North America Contract Development & Manufacturing Organization (CDMO) Market Value (USD billion), By Country, 2025 & 2034
  • Figure 13: North America Contract Development & Manufacturing Organization (CDMO) Market Value Share (%), By Country, 2025
  • Figure 14: Europe Contract Development & Manufacturing Organization (CDMO) Market Value (USD billion), by Service, 2025 & 2034
  • Figure 15: Europe Contract Development & Manufacturing Organization (CDMO) Market Value Share (%), by Service, 2025
  • Figure 16: Europe Contract Development & Manufacturing Organization (CDMO) Market Value (USD billion), by Molecule Type, 2025 & 2034
  • Figure 17: Europe Contract Development & Manufacturing Organization (CDMO) Market Value Share (%), by Molecule Type, 2025
  • Figure 18: Europe Contract Development & Manufacturing Organization (CDMO) Market Value (USD billion), by Therapeutic Area, 2025 & 2034
  • Figure 19: Europe Contract Development & Manufacturing Organization (CDMO) Market Value Share (%), by Therapeutic Area, 2026
  • Figure 20: Europe Contract Development & Manufacturing Organization (CDMO) Market Value (USD billion), By Country/Sub-region, 2025 & 2034
  • Figure 21: Europe Contract Development & Manufacturing Organization (CDMO) Market Value Share (%), By Country/Sub-region, 2025
  • Figure 22: Asia Pacific Contract Development & Manufacturing Organization (CDMO) Market Value (USD billion), by Service, 2025 & 2034
  • Figure 23: Asia Pacific Contract Development & Manufacturing Organization (CDMO) Market Value Share (%), by Service, 2025
  • Figure 24: Asia Pacific Contract Development & Manufacturing Organization (CDMO) Market Value (USD billion), by Molecule Type, 2025 & 2034
  • Figure 25: Asia Pacific Contract Development & Manufacturing Organization (CDMO) Market Value Share (%), by Molecule Type, 2025
  • Figure 26: Asia Pacific Contract Development & Manufacturing Organization (CDMO) Market Value (USD billion), by Therapeutic Area, 2025 & 2034
  • Figure 27: Asia Pacific Contract Development & Manufacturing Organization (CDMO) Market Value Share (%), by Therapeutic Area, 2026
  • Figure 28: Asia Pacific Contract Development & Manufacturing Organization (CDMO) Market Value (USD billion), By Country/Sub-region, 2025 & 2034
  • Figure 29: Asia Pacific Contract Development & Manufacturing Organization (CDMO) Market Value Share (%), By Country/Sub-region, 2025
  • Figure 30: Rest of the World Contract Development & Manufacturing Organization (CDMO) Market Value (USD billion), by Service, 2025 & 2034
  • Figure 31: Rest of the World Contract Development & Manufacturing Organization (CDMO) Market Value Share (%), by Service, 2025
  • Figure 32: Rest of the World Contract Development & Manufacturing Organization (CDMO) Market Value (USD billion), by Molecule Type, 2025 & 2034
  • Figure 33: Rest of the World Contract Development & Manufacturing Organization (CDMO) Market Value Share (%), by Molecule Type, 2025
  • Figure 34: Rest of the World Contract Development & Manufacturing Organization (CDMO) Market Value (USD billion), by Therapeutic Area, 2025 & 2034
  • Figure 35: Rest of the World Contract Development & Manufacturing Organization (CDMO) Market Value Share (%), by Therapeutic Area, 2026
  • Figure 36: Global Contract Development & Manufacturing Organization (CDMO) Market Share (%), By Company, 2025